#FDA approval

The targeted therapy shrank tumors in more than half of people with previously treated non-small-cell lung cancer.

The new credit card-size rapid antigen test can return results in 15 minutes.

More than 80% of clinical trial participants experienced complete or partial remission.

Guardant360 identifies patients with EGFR mutations, which could guide treatment decisions.

The antibody-drug-conjugate produced an overall response rate of 31%.

More than a third of people treated with Monjuvi plus Revlimid experienced complete remission.

Tecartus led to durable remission in a majority of participants in a Phase II study.

The combination improved both overall survival and patient-reported outcomes.

The regulatory agency requested further data to show whether its benefits outweigh its risks.

The American Cancer Society now calls for vaccination of girls and boys starting at age 9.

This represents an important advance for patients who previously needed to visit a health care facility.

The immunotherapy is now approved for people whose cancer has not progressed on platinum-based chemotherapy.

New injectable combination can be administered by health care providers outside medical centers.